TOKYO, Nov 15, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Japan Ltd announced today that a TV commercial will be ...

few more so than Eisai, which is developing a package of products and services in Japan for people living with dementia. Its latest venture is an alliance with Tokyo-based Lifenet Insurance Co ...

Eisai's digital tool to allow self-assessment of cognitive performance – NouKNOW – will be used in a Japanese project aimed ... be deployed in Bunkyo City, Tokyo in a dementia monitoring ...

Tokyo, Nov. 13 (Jiji Press)--Japan's Central Social Insurance Medical Council, which advises the health minister, approved ...

Lecanemab, the first medication designed to remove amyloid beta, a protein believed to cause Alzheimer’s, was developed by Japan’s Eisai Co. and its U.S. partner, Biogen Inc. “We believe ...

Eisai Co., Ltd. and Eisai’s corporate venture capital subsidiary, Eisai Innovation, Inc. announced today that Eisai ...

Japanese drugmaker Eisai is developing a dementia treatment that it aims to commercialise in the US by fiscal 2030, the Nikkei reported on Sunday. The new drug targets a protein called tau ...

The company was founded by Toyoji Naito in November 1936 and is headquartered in Tokyo, Japan. Read More on ESALF: Eisai NewsMORE Related Stocks Indices Commodities ...

Eisai shares climbed 3 percent Tokyo Wednesday morning while Biogen ... of the drug and will also seek approval in Europe and Japan.

1. About lecanemab (generic name, brand name: Leqembi®) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal ...

Japanese stocks are higher in morning trade, led by gains in tech and real-estate stocks. Concerns about funding costs ease following the Fed’s rate cut overnight. Recruit Holdings is up 3.7% and ...

Eisai Co., Ltd. and Biogen Japan Ltd announced today that a TV commercial will be broadcast nationwide in Japan from November 15 with the aim of increasing public ...